Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q7Z444
UPID:
RASE_HUMAN
Alternative names:
Embryonic stem cell-expressed Ras
Alternative UPACC:
Q7Z444
Background:
GTPase ERas, also known as Embryonic stem cell-expressed Ras, is pivotal in cellular processes, binding GDP/GTP with intrinsic GTPase activity. Its role is crucial in maintaining the tumor-like growth characteristics of embryonic stem cells, suggesting a significant function in cellular proliferation and differentiation.
Therapeutic significance:
Understanding the role of GTPase ERas could open doors to potential therapeutic strategies. Its involvement in the regulation of embryonic stem cell growth highlights its potential as a target for innovative treatments in regenerative medicine and cancer therapy.